NCT05654532View on ClinicalTrials.gov

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 29, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

May 31, 2026

Conditions
Breast Cancer
Interventions
DRUG

AC699

Participants will receive AC699 orally daily in 28-day cycles.

Trial Locations (9)

21044

Site 06, Rockville

23502

Site 05, Norfolk

32746

Site 07, Orlando

34232

Site 02, Sarasota

37203

Site 01, Nashville

77030

Site 03, Houston

78240

Site 09, San Antonio

80218

Site 08, Denver

98684

Site 04, Vancouver

Sponsors
All Listed Sponsors
lead

Accutar Biotechnology Inc

INDUSTRY

NCT05654532 - Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter